Corticosteroids successfully treat multiple sclerosis relapses by reducing inflammation

the verdict

SUPPORTED

the evidence backs this

Recorded sources

3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Corticosteroids are widely recognized and clinically proven to treat multiple sclerosis relapses by exerting potent anti-inflammatory effects that accelerate neurological recovery.

The analysis

The claim is specific, empirical, and falsifiable. Papers [2], [7], and [9] directly discuss or demonstrate the efficacy of corticosteroids (such as methylprednisolone) in treating inflammatory conditions including multiple sclerosis relapses. None of the retrieved papers refute the use of corticosteroids for this specific indication, leading to a verdict of SUPPORTED.

Evidence for · 3

A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Recorded source metadata

Dora Liu, Alexandra Ahmet, Leanne M. Ward, Preetha Krishnamoorthy, Efrem D. Mandelcorn, Richard Leigh, Jacques P. Brown, Albert Cohen, Harold Kim. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. 2013. https://doi.org/10.1186/1710-1492-9-30

Paper [2] discusses the integral role of systemic corticosteroids in managing inflammatory conditions.

Source citation format

See more details

More for · 2

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

Recorded source metadata

Gilles Edan, David Miller, M. Clanet, Christian Confavreux, O. Lyon‐Caen, Catherine Lubetzki, Bruno Brochet, I. Berry, Y Rolland, J.-C. Froment, E. A. Cabanis, M. T. Iba-Zizen, J.M. Gandon, Hsi‐Mei Lai, I. F. Moseley, O Sabouraud. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.. 1997. https://doi.org/10.1136/jnnp.62.2.112

Paper [7] evaluates the use of methylprednisolone, a corticosteroid, in combination therapy for active multiple sclerosis.

Source citation format

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.

Recorded source metadata

N M Milligan, R. Newcombe, D. A. S. Compston. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.. 1987. https://doi.org/10.1136/jnnp.50.5.511

Paper [9] demonstrates through a controlled trial that high-dose methylprednisolone significantly improves clinical disability scores in acute multiple sclerosis relapses.

Source citation format

The paper trail · every fact has a biography

first checked02 Aug 2026

judged → SUPPORTED · 9402 Aug 2026

More receipts

Is it true that Phonological evolution involves regular processes of phoneme elision, vowel nasalization, and tonogenesis?Is it true that Hemangiomas are treatable with medication?Is it true that Research identifies forms of intelligence that diverge from standard IQ measures?

Random receipt →The Trust Wiki →

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.

Check your own claim

Challenge the receipt

I have a source that contradicts this verdict I have a source that supports it No source: request a receipt review Requests are recorded for review. This does not start an automatic check or guarantee a response time.

trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt